Latest GLP-1 Therapies Research Papers | Page 16 | OpenScience.ink

4 weeks ago • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Use and prescribing patterns of incretin-like diabetes drugs in mostly Hispanic/Latino patients with type 2 diabetesIncretin Mimetics for Patients Living with Type 2 Diabetes in a Predominantly Hispanic/Latino Population: Analysis of Prescribing Frequency and Predictors of Use.

📖 Top 50% JournalArticle

1 month ago • Nature medicine

Oral diabetes drug safiglipron compared to dapagliflozin in type 2 diabetes: a phase 3 randomized trialOral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial.

Article

1 month ago • Reviews of physiology, biochemistry and pharmacology

Amino Acids in Obesity and Fatty Liver Disease Linked to Metabolic ProblemsAA in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Nonalcoholic Fatty Liver Disease (NAFLD).

Article

1 month ago • Cureus

Comparing the effectiveness and safety of Liraglutide and Metformin in women with polyendocrine metabolic ovarian syndromeComparative Efficacy and Safety of Liraglutide Versus Metformin in Women With Polyendocrine Metabolic Ovarian Syndrome (PMOS): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Article

1 month ago • Obesity pillars

Clinical importance of lowest weight and weight regain over 3 years of tirzepatide treatment in people with obesity or overweight and prediabetesEvaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.

📖 Top 20% JournalArticle

1 month ago • European heart journal

Semaglutide reduces heart and liver changes in heart failure with preserved pumping strength, independent of weight lossSemaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction.

🥇 Top 1% JournalArticle

1 month ago • Turkish journal of surgery

How GLP-1 receptor drugs may affect cosmetic surgery practiceEffects of GLP-1 receptor agonists on aesthetic surgery practice: A contemporary review.

Article

1 month ago • Peptides

Two-Way Drug Effects on the GIP Receptor in Obesity: History, Different Mechanisms, and Challenges for TreatmentBidirectional pharmacology of GIP receptor targeting in obesity: Historical foundations, mechanistic divergence, and translational boundaries.

Article

1 month ago • Advances in therapy

How Medicaid Patients Follow and Factors Affecting Use of GLP-1 Drugs for Managing ObesityReal-World Adherence Patterns and Predictors of GLP-1 Receptor Agonist Use for Obesity Management in a Medicaid Population.

📖 Top 20% JournalArticle

1 month ago • JAMA pediatrics

Weight-Loss Surgery and Use of Blood Sugar Control Medicines in TeenagersMetabolic and Bariatric Surgery and GLP-1 Receptor Agonist Use Among Adolescents.

🥇 Top 1% JournalArticle

1 month ago • European journal of internal medicine

New comprehensive treatment approaches for creatine kinase muscle diseaseInnovative holistic treatment for CKM: what lies ahead?

📖 Top 20% JournalArticle

1 month ago • Pharmacology research & perspectives

How Glucagon-Like Peptide-1 Drugs May Influence Blood Pressure and Heart HealthGlucagon-Like Peptide-1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications.

📖 Top 30% JournalArticle

1 month ago • Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir

Using GLP-1 and Dual GIP/GLP-1 Medicines for Obesity: Practical Advice for DoctorsPractical Considerations for the Use of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity: A Clinician-Oriented Guide.

Article

1 month ago • EClinicalMedicine

Stroke risk linked to SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors in people with type 2 diabetes in SwedenThe effect of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors on stroke risk in type 2 diabetes: a nationwide longitudinal cohort study in Sweden with contextualisation analysis.

🥈 Top 2% JournalArticle

1 month ago • Health affairs (Project Hope)

Spending Growth in a Large Massachusetts Insurer Caused by More and More Intense CareSpending Growth In A Large Massachusetts Insurer Driven By Volume And Intensity.

Article

1 month ago • Drug design, development and therapy

Risk of New Dementia in COVID-19 Survivors with Type 2 Diabetes Using GLP-1 Receptor Agonists Compared to DPP-4 InhibitorsGLP-1 Receptor Agonists Versus DPP-4 Inhibitors and Incident Dementia Risk in COVID-19 Survivors with Type 2 Diabetes: A Target Trial Emulation Study.

📖 Top 20% JournalComparative Study

1 month ago • American journal of preventive cardiology

Study setup and starting details of a phase 3 trial testing the oral drug orforglipron for high blood pressureStudy design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension.

🥉 Top 5% JournalArticle

1 month ago • Best practice & research. Clinical rheumatology

New understanding of how osteoporosis develops and personalized treatment approachesNew insights into the pathogenesis of osteoporosis and the translational approach to personalized therapy.

🎖️ Top 10% JournalArticle

1 month ago • Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association

How Cell Recycling and Gene Regulation in Brain Hunger Centers May Explain Ongoing Obesity and Treatment ChallengesThe Autophagy-Epigenome Axis in Hypothalamic Neurons: A Unified Framework for Understanding Obesity Persistence and Therapeutic Resistance.

📖 Top 50% JournalArticle

← prevpage 16 of 16next →